Combined therapy with ligustrazine and paeonol mitigates hepatic fibrosis through destroying mitochondrial integrity of stellate cell.

This study investigates the inhibitory effect and potential mechanism of ligustrazine combined with paeonol on hepatic fibrosis, as to provide a new therapeutic strategy for clinical hepatic fibrosis. The degree of liver injury collagen deposition and inflammation was assessed by hematoxylin and eosin staining, Masson, Sirius red staining and biochemically serum analysis. ATP and ROS levels in each group were detected by chemical fluorescence method. The apoptotic rate was measured by Tunel assay. Mito-Tacker fluorescence staining and mitochondrial DNA copy number were measured to observe the effect of ligustrazine or/and paeonol on mitochondrial function of hepatic stellate cell (HSC). The expression of relevant proteins and genes were evaluated by using immunofluorescence RT-PCR and western blot. Ligustrazine or/and paeonol significantly improve the pathological changes in liver tissue induced by CCl4, however, they reduced the levels of liver and fibrosis markers in tissue and serum. ROS, NOX1 and NOX2 were significantly increased and GSH was decreased in HSC, with the intervention of Ligustrazine or/and paeonol. We further found that Ligustrazine or/and paeonol can effectively inhibit liver inflammation in vivo. The expression of TNF-α, IL-6 and IL-8 was upregulated in HSC. Moreover, Ligustrazine or/and paeonol promotes apoptosis and inhibit proliferation of HSC. Additionally, the inhibiting effects of the drug on collagen deposition was due to the interference with the expression of signaling pathway related proteins and genes such as, MMPS, TGF-β, PDGF and BMP-2 in HSC. Mitochondrial activity of HSC was inhibited by Ligustrazine or/and paeonol. The inhibitory effects of ligustrazine or/and Paeonol on mitochondrial function is partially balanced by mitochondrial protective agent SS-31. Ligustrazine combined with paeonol exerts significant anti-hepatic fibrosis effect in vivo and in vitro. This may due to the disruption of HSC mitochondrial function, thereby induced promoting oxidative stress, apoptosis, inflammation and inhibiting the formation and deposition of extracellular matrix.

[1]  Xiaoying Wang,et al.  Pien-Tze-Huang ameliorates hepatic fibrosis via suppressing NF-κB pathway and promoting HSC apoptosis. , 2019, Journal of ethnopharmacology.

[2]  A. El-Karef,et al.  Antioxidant and anti-inflammatory activities of berberine attenuate hepatic fibrosis induced by thioacetamide injection in rats. , 2018, Chemico-biological interactions.

[3]  Chang Xu,et al.  TAZ inhibition promotes IL-2-induced apoptosis of hepatocellular carcinoma cells by activating the JNK/F-actin/mitochondrial fission pathway , 2018, Cancer Cell International.

[4]  Qiang He,et al.  Breviscapine ameliorates CCl4-induced liver injury in mice through inhibiting inflammatory apoptotic response and ROS generation , 2018, International journal of molecular medicine.

[5]  Xuan Zhu,et al.  Ursolic acid ameliorates CCl4‐induced liver fibrosis through the NOXs/ROS pathway , 2018, Journal of cellular physiology.

[6]  Lu Zhang,et al.  Anti-fibrotic role and mechanism of Periplaneta americana extracts in CCl4-induced hepatic fibrosis in rats , 2018, Acta biochimica et biophysica Sinica.

[7]  Feng Zhang,et al.  Ligand Activation of PPARγ by Ligustrazine Suppresses Pericyte Functions of Hepatic Stellate Cells via SMRT-Mediated Transrepression of HIF-1α , 2018, Theranostics.

[8]  Qi Wang,et al.  Hepatocellular toxicity of oxalicumone A via oxidative stress injury and mitochondrial dysfunction in healthy human liver cells , 2017, Molecular medicine reports.

[9]  A. Yang,et al.  Stachydrine ameliorates carbon tetrachloride-induced hepatic fibrosis by inhibiting inflammation, oxidative stress and regulating MMPs/TIMPs system in rats. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  L. Feldman,et al.  Mitochondria Protection after Acute Ischemia Prevents Prolonged Upregulation of IL-1β and IL-18 and Arrests CKD. , 2017, Journal of the American Society of Nephrology : JASN.

[11]  Jian Liang,et al.  Modulation of hepatic stellate cells and reversibility of hepatic fibrosis , 2017, Experimental cell research.

[12]  Yongfang Yuan,et al.  Antifibrotic effects of tanshinol in experimental hepatic fibrosis by targeting PI3K/AKT/mTOR/p70S6K1 signaling pathways. , 2017, Discovery medicine.

[13]  T. Pan,et al.  Ankaflavin and Monascin Induce Apoptosis in Activated Hepatic Stellate Cells through Suppression of the Akt/NF-κB/p38 Signaling Pathway. , 2016, Journal of agricultural and food chemistry.

[14]  Xiao-ya Liu,et al.  Fibronectin expression is critical for liver fibrogenesis in vivo and in vitro , 2016, Molecular medicine reports.

[15]  Li Wu,et al.  Dihydroartemisinin alleviates bile duct ligation-induced liver fibrosis and hepatic stellate cell activation by interfering with the PDGF-βR/ERK signaling pathway. , 2016, International immunopharmacology.

[16]  Liang-bing Wei,et al.  Panax notoginseng saponins ameliorates experimental hepatic fibrosis and hepatic stellate cell proliferation by inhibiting the Jak2/ Stat3 pathways. , 2016, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.

[17]  F. Lu,et al.  Anti-fibrotic effects of specific-siRNA targeting of the receptor for advanced glycation end products in a rat model of experimental hepatic fibrosis. , 2014, Molecular medicine reports.

[18]  Feng Zhang,et al.  Paeonol inhibits hepatic fibrogenesis via disrupting nuclear factor‐κB pathway in activated stellate cells: In vivo and in vitro studies , 2013, Journal of Gastroenterology and Hepatology.

[19]  Lei Dong,et al.  Chlorogenic acid reduces liver inflammation and fibrosis through inhibition of toll-like receptor 4 signaling pathway. , 2013, Toxicology.